Vir Biotechnology Inc. [NASDAQ: VIR] price plunged by -5.68 percent to reach at -$1.85. The company report on December 18, 2020 that Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19.
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with COVID-19 –.
Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced that the first patient has been dosed in a new sub-trial of the National Institutes of Health’s (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Program Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of VIR-7831 for the treatment of hospitalized adults with COVID-19. VIR-7831 (also known as GSK4182136) is a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) investigational monoclonal antibody that was selected based on its potential to neutralize the virus, kill infected cells, provide a high barrier to resistance and achieve high concentrations in the lungs (one of the major sites of infection).
A sum of 5354649 shares traded at recent session while its average daily volume was at 968.11K shares. Vir Biotechnology Inc. shares reached a high of $33.30 and dropped to a low of $30.41 until finishing in the latest session at $30.71.
Guru’s Opinion on Vir Biotechnology Inc. [VIR]:
BofA Securities have made an estimate for Vir Biotechnology Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 05, 2020. While these analysts kept the previous recommendation, Goldman raised their target price from $48 to $54. The new note on the price target was released on September 14, 2020, representing the official price target for Vir Biotechnology Inc. stock. Previously, the target price had yet another raise to $29, while JP Morgan analysts kept a Neutral rating on VIR stock.
The Average True Range (ATR) for Vir Biotechnology Inc. is set at 1.99, with the Price to Sales ratio for VIR stock in the period of the last 12 months amounting to 54.86. The Price to Book ratio for the last quarter was 4.75, with the Price to Cash per share for the same quarter was set at 6.12.
VIR Stock Performance Analysis:
Vir Biotechnology Inc. [VIR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.42. With this latest performance, VIR shares gained by 11.71% in over the last four-week period, additionally sinking by -21.03% over the last 6 months – not to mention a rise of 148.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VIR stock in for the last two-week period is set at 48.32, with the RSI for the last a single of trading hit 47.26, and the three-weeks RSI is set at 47.85 for Vir Biotechnology Inc. [VIR]. The present Moving Average for the last 50 days of trading for this stock 32.28, while it was recorded at 32.00 for the last single week of trading, and 36.82 for the last 200 days.
Insight into Vir Biotechnology Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Vir Biotechnology Inc. [VIR] shares currently have an operating margin of -2144.35. Vir Biotechnology Inc.’s Net Margin is presently recorded at -2158.98.
Return on Total Capital for VIR is now -62.52, given the latest momentum, and Return on Invested Capital for the company is -62.97. Return on Equity for this stock declined to -63.07, with Return on Assets sitting at -49.65. When it comes to the capital structure of this company, Vir Biotechnology Inc. [VIR] has a Total Debt to Total Equity ratio set at 0.27. Additionally, VIR Total Debt to Total Capital is recorded at 0.27, with Total Debt to Total Assets ending up at 0.22. Long-Term Debt to Equity for the company is recorded at 0.21, with the Long-Term Debt to Total Capital now at 0.21.
Reflecting on the efficiency of the workforce at the company, Vir Biotechnology Inc. [VIR] managed to generate an average of -$762,808 per employee.Vir Biotechnology Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 11.00 and a Current Ratio set at 11.00.
VIR Stock EPS
With the latest financial reports released by the company, Vir Biotechnology Inc. posted -0.69/share EPS, while the average EPS was predicted by analysts to be reported at -0.67/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -3.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VIR. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vir Biotechnology Inc. go to 8.50%.
Vir Biotechnology Inc. [VIR] Insider Position Details
There are presently around $2,133 million, or 79.60% of VIR stock, in the hands of institutional investors. The top three institutional holders of VIR stocks are: SB INVESTMENT ADVISERS (UK) LTD with ownership of 22,616,666, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; CAPITAL INTERNATIONAL INVESTORS, holding 11,283,094 shares of the stock with an approximate value of $346.5 million in VIR stocks shares; and VANGUARD GROUP INC, currently with $169.94 million in VIR stock with ownership of nearly 1437.616% of the company’s market capitalization.
Positions in Vir Biotechnology Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 84 institutional holders increased their position in Vir Biotechnology Inc. [NASDAQ:VIR] by around 19,041,956 shares. Additionally, 47 investors decreased positions by around 2,310,909 shares, while 12 investors held positions by with 48,087,297 shares. The mentioned changes placed institutional holdings at 69,440,162 shares, according to the latest SEC report filing. VIR stock had 36 new institutional investments in for a total of 1,090,101 shares, while 26 institutional investors sold positions of 2,007,189 shares during the same period.